# Jnana Therapeutics (United States)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/jnana-therapeutics-united-states/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 51.7 |
| Citations | 7,762 |
| City | Boston |
| Country | United States |
| Description | Jnana Therapeutics (United States) is a research organisation in Boston, United States. OpenAlex records 63 works and 7,762 citations for it. 3 researchers list it as their most recent affiliation. |
| Homepage | https://www.jnanatx.com/ |
| OpenAlex ID | https://openalex.org/I4210105831 |
| Region | Massachusetts |
| Researchers | 3 |
| ROR ID | https://ror.org/01mvsyt14 |
| Type | company |
| Works | 63 |

## University papers

- [The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity](https://scholariq.org/papers/the-cancer-cell-line-encyclopedia-enables-predictive-modelling-of-anticancer/)
- [Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages](https://scholariq.org/papers/revised-classification-of-histiocytoses-and-neoplasms-of-the-macrophage/)
- [Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer](https://scholariq.org/papers/phase-ii-pilot-study-of-vemurafenib-in-patients-with-metastatic-i-braf-i-mutated/)
- [Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative](https://scholariq.org/papers/personalized-medicine-in-a-phase-i-clinical-trials-program-the-md-anderson/)
- [Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-<i>N</i>2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-<i>N</i>4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials](https://scholariq.org/papers/synthesis-structure-activity-relationships-and-in-vivo-efficacy-of-the-novel/)
- [Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia](https://scholariq.org/papers/requirement-of-src-kinases-lyn-hck-and-fgr-for-bcr-abl1-induced-b-lymphoblastic/)
- [Intratumoral injection of <i>Clostridium novyi</i> -NT spores induces antitumor responses](https://scholariq.org/papers/intratumoral-injection-of-i-clostridium-novyi-i-nt-spores-induces-antitumor/)
- [Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial](https://scholariq.org/papers/vorasidenib-a-dual-inhibitor-of-mutant-idh1-2-in-recurrent-or-progressive-glioma/)

## University researchers

- [David Lyon](https://scholariq.org/researchers/david-lyon/)
- [Filip Jankú](https://scholariq.org/researchers/filip-janku/)
- [Markus Warmuth](https://scholariq.org/researchers/markus-warmuth/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.